Engineered Nanomaterials in Food and Drugs

This book pans through three major sections of materials and methods used in the engineering of nanomaterials-their applications, ethical issues, and present market share in the field of food and drugs. It presents information on the kind of materials and processes that are used to synthesize nanomaterials, which are eventually used in the food and drug industries. It chalks out the minor details of components and parameters that could influence the outcome in terms of dimension, surface property, toxicity, stability, bioavailability, degradation, physiological responsiveness, etc.
It also gives input about what to do and what not to do while preparing an engineered nanomaterial for food or drug applications. It describes the previous and current uses of engineered nanomaterials and the advancements in this area in the past few years. It comprehensively details the applications of nanomaterials in various areas, such as in drug delivery and theranostics, particularly in cancer diagnostics and neurodegenerative disorders. It also briefly discusses the use of nanotechnology in the area of radiopharmaceuticals, providing an insight into the requirements for the design of any nanomaterial to be capable of being a potential candidate for the discussed applications. It talks about the ethical issues and parameters to be evaluated before taking any nanomaterial to the market, considering the importance of establishing the safety of consumers who are exposed to nanomaterials due to the increased use of nanotechnology in all facets of life. It discusses the emerging applications of nanomaterials in the areas of healthcare (therapeutics and diagnostics), the food industry (from farm to table), and personal hygiene (daily personal care products to cosmetics). It also provides a snapshot of the precautions to be taken while working with nanomaterials and describes the ongoing efforts to harmonize the global standards for the risk and safety assessment of this emerging technology.

Santosh K. Misra is an associate professor at the Department of Biological Sciences and Bioengineering, Indian Institute of Technology, Kanpur, India. He received his postdoctoral and research scientist training at the Department of Bioengineering, University of Illinois at Urbana-Champaign, Illinois, USA. He earned his PhD from the Indian Institute of Science (IISc), Bangalore, India. His research training involved the fields of nanomedicine, biomaterials, biomedical devices, and personalized medicine approaches. He has more than 90 research publications, multiple filed/granted patents, book chapters, and extramural national and international funding to his credit from various reputed agencies.
Nishima Wangoo is an assistant professor at the Department of Applied Sciences (Chemistry), University Institute of Engineering and Technology (UIET), Panjab University, Chandigarh, India. She earned her PhD in the area of nanoscience and nanotechnology from the Institute of Microbial Technology (CSIR-IMTECH), India. She also has significant scientific experience as a researcher at Northwestern University, Illinois, USA, and as a postdoctoral researcher at Nanyang Technological University, Singapore. She has 70 international publications and several book chapters to her credit. She has completed 10 extramural research projects while 3 are ongoing.
Sangeeta Khare is a principal investigator/research microbiologist at the National Center for Toxicological Research/U. S. Food and Drug Administration (US-FDA), where she leads an active team working on host-pathogen/host-microbiome interaction. She earned her PhD in the area of infectious diseases from the All India Institute of Medical Sciences, New Delhi, India. She studied infectious agent/gastrointestinal pathogen-host interaction at the University of Saskatchewan, Canada, and Texas A&M University, College Station, Texas, USA. Dr Khare has authored over 100 peer-reviewed works, including book chapters and technical reports, contributing significantly to the public health by supporting FDA Strategic Goal to modernize regulatory science with emerging technology and innovation.